

# Yohan Suryo Rahmanto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7876728/publications.pdf>

Version: 2024-02-01

46  
papers

2,996  
citations

126907

33  
h-index

233421

45  
g-index

48  
all docs

48  
docs citations

48  
times ranked

4703  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy. <i>IScience</i> , 2021, 24, 103297.	4.1	12
2	Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers. <i>Cancer Research</i> , 2020, 80, 4514-4526.	0.9	44
3	Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. <i>Nature Communications</i> , 2020, 11, 2717.	12.8	45
4	Acireductone dioxygenase 1 (ADI1) is regulated by cellular iron by a mechanism involving the iron chaperone, PCBP1, with PCBP2 acting as a potential co-chaperone. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165844.	3.8	8
5	Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer. <i>EBioMedicine</i> , 2019, 47, 184-194.	6.1	9
6	Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 5584-5594.	7.0	80
7	TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2 $\beta$ as a therapeutic target. <i>Journal of Pathology</i> , 2019, 248, 363-376.	4.5	23
8	Therapeutic Inducers of Apoptosis in Ovarian Cancer. <i>Cancers</i> , 2019, 11, 1786.	3.7	44
9	Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2019, 1863, 371-378.	2.4	37
10	Relationship between ovarian cancer stem cells, epithelial mesenchymal transition and tumour recurrence. , 2019, 2, 1127-1135.		3
11	Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway. <i>Oncogene</i> , 2018, 37, 3778-3789.	5.9	22
12	Coupling of the polyamine and iron metabolism pathways in the regulation of proliferation: Mechanistic links to alterations in key polyamine biosynthetic and catabolic enzymes. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 2793-2813.	3.8	41
13	Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma. <i>Human Pathology</i> , 2017, 68, 87-91.	2.0	19
14	Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer. <i>Oncotarget</i> , 2017, 8, 72147-72156.	1.8	49
15	Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells. <i>Journal of Biological Chemistry</i> , 2016, 291, 9690-9699.	3.4	45
16	Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 186-193.	3.0	38
17	ARID1A (AT rich interactive domain 1A (SWI-like)). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2014, , .	0.1	0
18	Roles of Deletion of Arid1a, a Tumor Suppressor, in Mouse Ovarian Tumorigenesis. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	105

#	ARTICLE	IF	CITATIONS
19	Hepcidin Bound to $\alpha_2$ -Macroglobulin Reduces Ferroportin-1 Expression and Enhances Its Activity at Reducing Serum Iron Levels. <i>Journal of Biological Chemistry</i> , 2013, 288, 25450-25465.	3.4	22
20	N-myc Downstream Regulated 1 (NDRG1) Is Regulated by Eukaryotic Initiation Factor 3a (eIF3a) during Cellular Stress Caused by Iron Depletion. <i>PLoS ONE</i> , 2013, 8, e57273.	2.5	59
21	Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 20590-20595.	7.1	85
22	Nitric Oxide Storage and Transport in Cells Are Mediated by Glutathione S-Transferase P1-1 and Multidrug Resistance Protein 1 via Dinitrosyl Iron Complexes. <i>Journal of Biological Chemistry</i> , 2012, 287, 607-618.	3.4	50
23	Iron Chelators for the Treatment of Cancer. <i>Current Medicinal Chemistry</i> , 2012, 19, 2689-2702.	2.4	158
24	Melanotransferrin: Search for a function. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2012, 1820, 237-243.	2.4	46
25	Nitrogen Monoxide (NO) Storage and Transport by Dinitrosyl-Dithiol-Iron Complexes: Long-lived NO That Is Trafficked by Interacting Proteins. <i>Journal of Biological Chemistry</i> , 2012, 287, 6960-6968.	3.4	60
26	Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy. <i>British Journal of Pharmacology</i> , 2012, 165, 148-166.	5.4	90
27	Siderocalin/Lcn2/NGAL/24p3 Does Not Drive Apoptosis Through Gentisic Acid Mediated Iron Withdrawal in Hematopoietic Cell Lines. <i>PLoS ONE</i> , 2012, 7, e43696.	2.5	45
28	The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 483-499.	2.1	69
29	The Potent and Novel Thiosemicarbazone Chelators Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-Benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone Affect Crucial Thiol Systems Required for Ribonucleotide Reductase Activity. <i>Molecular Pharmacology</i> , 2011, 79, 921-931.	2.3	44
30	Cellular Iron Depletion and the Mechanisms Involved in the Iron-dependent Regulation of the Growth Arrest and DNA Damage Family of Genes. <i>Journal of Biological Chemistry</i> , 2011, 286, 35396-35406.	3.4	39
31	The ins and outs of mitochondrial iron-loading: the metabolic defect in Friedreich's ataxia. <i>Journal of Molecular Medicine</i> , 2010, 88, 323-329.	3.9	55
32	The translational regulator eIF3a: The tricky eIF3 subunit!. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1806, 275-286.	7.4	41
33	Iron Chelator-Mediated Alterations in Gene Expression: Identification of Novel Iron-Regulated Molecules That Are Molecular Targets of Hypoxia-Inducible Factor-1 $\alpha$ and p53. <i>Molecular Pharmacology</i> , 2010, 77, 443-458.	2.3	64
34	Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 10775-10782.	7.1	413
35	Elucidation of the mechanism of mitochondrial iron loading in Friedreich's ataxia by analysis of a mouse mutant. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 16381-16386.	7.1	197
36	Generation and characterization of transgenic mice hyper-expressing melanoma tumour antigen p97 (Melanotransferrin): No overt alteration in phenotype. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2009, 1793, 1210-1217.	4.1	13

#	ARTICLE	IF	CITATIONS
37	Hepcidin, the hormone of iron metabolism, is bound specifically to $\alpha_2$ -macroglobulin in blood. <i>Blood</i> , 2009, 113, 6225-6236.	1.4	111
38	Biochemical and spectroscopic studies of human melanotransferrin (MTf): Electron-paramagnetic resonance evidence for a difference between the iron-binding site of MTf and other transferrins. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 2739-2745.	2.8	11
39	The MCK mouse heart model of Friedreich's ataxia: Alterations in iron-regulated proteins and cardiac hypertrophy are limited by iron chelation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 9757-9762.	7.1	113
40	Identification of distinct changes in gene expression after modulation of melanoma tumor antigen p97 (melanotransferrin) in multiple models in vitro and in vivo. <i>Carcinogenesis</i> , 2007, 28, 2172-2183.	2.8	34
41	Differential regulation of the Menkes and Wilson disease copper transporters by hormones: an integrated model of metal transport in the placenta. <i>Biochemical Journal</i> , 2007, 402, e1-3.	3.7	8
42	The melanoma tumor antigen, melanotransferrin (p97): a 25-year hallmark " from iron metabolism to tumorigenesis. <i>Oncogene</i> , 2007, 26, 6113-6124.	5.9	53
43	Iron uptake and metabolism in the new millennium. <i>Trends in Cell Biology</i> , 2007, 17, 93-100.	7.9	343
44	Role of melanotransferrin in iron metabolism: studies using targeted gene disruption in vivo. <i>Blood</i> , 2006, 107, 2599-2601.	1.4	39
45	Resistance to the Antineoplastic Agent Gallium Nitrate Results in Marked Alterations in Intracellular Iron and Gallium Trafficking: Identification of Novel Intermediates. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 153-162.	2.5	36
46	The function of melanotransferrin: a role in melanoma cell proliferation and tumorigenesis. <i>Carcinogenesis</i> , 2006, 27, 2157-2169.	2.8	69